PAC326-A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytopenia Myelofibrosis

  • Jana, Bagi, (PI)

    Project: Other project

    StatusFinished
    Effective start/end date3/2/153/1/17

    Funding

    • CTI BioPharma Corp.: $4,846.15